Panel Discussion | Pharma’s Appetite for Innovation: What do Global Partners Seek in Novel Targets and Modalities?

• Which CNS indications and targets hold the greatest promise for investable disease‑modifying therapies?
• What stage and type of data are needed to confidently support safety, target engagement, and MoA of new targets under evaluation?
• Do you prioritize new modalities aligned with in‑house expertise, or are you open to partnering with specialists in novel modalities?

Speakers:

Zhaomin Chen

Former Head of Research External Innovation

Sanofi

Seoeun Lee

Senior Director, External Innovation

Eli Lilly & Co.

Jiro Matsumura

Director Regional Search & Evaluation

Novartis AG

Lisa Li

Associate Director, Early-Stage Partnering Japan, Strategy & Portfolio Development

Takeda Pharmaceutical

Whitney Michiels

VP, Neuroscience External Innovation

Johnson & Johnson